Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
Farastuk Bozorgmehr,
Inn Chung,
Petros Christopoulos,
Johannes Krisam,
Marc A. Schneider,
Lena Brückner,
Daniel Wilhelm Mueller,
Michael Thomas,
Stefan Rieken
Affiliations
Farastuk Bozorgmehr
Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg
Inn Chung
Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg
Petros Christopoulos
Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg
Johannes Krisam
Institute of Medical Biometry and Informatics, University Hospital of Heidelberg
Marc A. Schneider
Translational Lung Research Center Heidelberg TLRCH, Member of the german Center for Lung Research DZL
Lena Brückner
Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg
Daniel Wilhelm Mueller
Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital
Michael Thomas
Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg
Stefan Rieken
Department of Radiation Oncology, University Medical Center Göttingen
